Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Entellus’ ENT portfolio is led by e XprESS Multi-Sinus Dilation System and the LATERA Absorbable Nasal Implant.
Pfizer is no stranger to taking the big gambles-note the company’s attempts to buy Astra in 2014 and Allergan in 2016.
The revised offer of $49.25 per share represents an increase of 17.3 percent to the previously announced $42 per share, the company said.
Siemens Healthineers, the German industrial conglomerate’s largest and most profitable division, is worth roughly $47.49 billion.
Astellas is pulling the trigger on an acquisition option from a partnership deal the two companies formed in 2013.
Genmab just received a $20M milestone payment from Janssen Biotech.
The company has snapped up manufacturing space in North Carolina’s Research Triangle Park to internally produce lentiviral vector for the company’s gene and cell therapies.
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics.
A look at why a potential buyout of Acadia might not be as likely as some have suggested.
Kenneth Pittman, writing for Seeking Alpha, takes a look at why Shire is thinking of unloading its neuroscience division and suggesting an alternative.